Clinical Trials: Current Open Trials
Listed by disease type - Last updated: 12/12/2005

Clinical Trials Home | Current Open Trials | Prevention Trials Institutional Review Board (IRB) | Featured Study | Staff History | Links of Interest

Breast Cancer Prevention (Back to Top)
Protocol	Description
No Current Clinical Trials in this Area.
Breast Cancer (Back to Top)
Protocol	Description
Aventis XRP9881B	(Phase II) Metastatic breast cancer progressing after therapy with Anthracycline, Taxane, Capecitabine: IV RPR109881 (Contact Sue Bales, RN, Coordinator, 865-541-1893)
BMS CA163-048	(Phase III) Advanced breast cancer previously treated with Anthracycline and Taxane: Novel Epothilone BMS 247550 plus Capecitabine vs. Capecitabine alone (Contact Sue Bales, RN, Coordinator, 865-541-1893)
CTSU C40101	(Phase III) Adjuvant, node-negative breast cancer: Cyclophosphamide and Doxorubicin (CA 4 vs. 6 cycles) vs. Taxol (4 vs. 6 cycles)
CTSU C49907	(Phase III) Adjuvant, node positive or negative women 65 years or older: Adjuvant chemotherapy with standard regimens, Cyclophosphamide, Methotrexate and Fluorouracil (CMF), or Doxorubicin and Cyclophosphamide (AC), vs. Capecitabine
CTSU C70301	Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer (Companion to CALGB 40101)
GSK EGF30008	(Phase III) ER/PR positive, advanced or metastatic breast cancer: Oral GW572016 in combination with Letrozole vs. Letrozole/placebo (provided) (Contact Sue Bales, RN, Coordinator, 865-541-1893)
NSABP B-35	Postmenopausal women with DCIS undergoing lumpectomy with radiation therapy: Anastrazole vs. Tamoxifen
NSABP B-38	(Phase III) Adjuvant, node-positive breast cancer: Randomized study of three different adjuvant chemotherapy regimens: Docetaxel, Doxorubicin, and Cyclophosphamide vs. Dose-Dense Doxorubicin, Cyclophosphamide, and Paclitaxel vs. Dose-Dense Doxorubicin, Cyclophosphamide, Paclitaxel, and Gemcitabine
NSABP B-39/RTOG 0413	(Phase III) Stage 0, I, II breast cancer: Conventional whole breast irradiation vs. partial breast irradiation
Sarah Cannon BRE 43	(Phase II) First relapse, metastatic breast: Randomized crossover study of Doxorubicin Liposoma (Doxil®) vs. weekly Docetaxel (Taxotere®)
Central Nervous System (Back to Top)
Protocol	Description
No Current Clinical Trials in this Area.
Esophageal Cancer (Back to Top)
Protocol	Description
No Current Clinical Trials in this Area.
Gastrointestinal Disease (Back to Top)
Protocol	Description
BMS CA225006	(Phase III) 2nd line Metastatic EGFR-Positive Colorectal: Irinotecan and Cetuximab vs. Irinotecan (Contact Sue Bales, RN, Coordinator, 865-541-1893)
CTSU N0147	(Phase III) Curative resection for stage III colon cancer: Comparison of combination chemotherapy regimens with or without Cetuximab in treating patients who have undergone surgery for stage III colon cancer
CTSU E4201	(Phase III) Localized unresectable pancreatic cancer: Gemcitabine plus radiation vs. Gemcitabine alone
CTSU Z9001	(Phase III) Gastrointestinal Stromal Tumor: Adjuvant STI571 (Gleevec™) vs. placebo
NSABP C-08	Phase III, Resected Stages II and III Cancer of the Colon: 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX6) with Bevacizumab every two weeks compared to the same regimen without Bevacizumab.
SWOG 0205	(Phase III) Advanced pancreatic cancer: Gemcitabine plus C225 vs. Gemcitabine alone
Genitourinary (Back to Top)
Protocol	Description
SWOG 9346	(Phase III) Stage D2 prostate cancer: Intermittent vs. continuous combined androgen-deprivation therapy comprising Bicalutamide and Goserelin
Gynecologic Cancers (Back to Top)
Protocol	Description
No Current Clinical Trials in this Area.
Head and Neck (Back to Top)
Protocol	Description
RTOG 0234	(Phase II) Randomized trial of surgery followed by chemoradiotherapy plus C225 (cetuximab) for advanced squamous cell carcinoma of the head and neck
Leukemia (Back to Top)
Protocol	Description
SWOG S0301	(Phase II) Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in patients age 56 or older: Induction with Daunorubicin, Cytarabine and Cyclosporine by continuous IV infusion
Non-Small Cell Lung Cancer (Back to Top)
Protocol	Description
SK&F 104864-A/615	(Phase III) Second line Advanced (Stage IIIB/IV) NSCLC: Combination IV Topotecan/Docetaxel vs. Docetaxel alone (Contact Sue Bales, RN, Coordinator, 865-541-1893)
SWOG 0424	Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
TCSC-RT 0301	A Pilot Study of Reduced Treatment Time in Patients with NSCLC using Image Guided Helical TomoTherapy
Small-Cell Lung Cancer (Back to Top)
Protocol	Description
SWOG 0124	(Phase III) Extensive Small Cell Lung Cancer: Cisplatin and Irinotecan vs. Cisplatin and Etoposide
Lymphoma (Back to Top)
Protocol	Description
SWOG E2496	(Phase III) Locally extensive and advanced stage Hodgkin's Disease (0 - 2 risk factors): ABVD vs. Stanford V with or without radiation therapy
SWOG S9704	(Phase III) Diffuse, Aggressive Non-Hodgkin's Lymphoma (High-Intermediate/High Risk Group): Early high dose chemotherapy and Autologous Stem Cell Transplant vs. conventional dose CHOP chemotherapy plus Rituximab for CD20 + B Cell Lymphomas (with possible late Autologous Stem Cell Transplant)
Melanoma (Back to Top)
Protocol	Description
SWOG E1697	(Phase III) Randomized study of four weeks of high dose IFN-alpha2b in stage T3-T4 or N1 (microscopic) melanoma
SWOG S0008	(Phase III) High Risk Melanoma: High Dose Interferon Alpha-2b vs. Cisplatin, Vinblastine, DTIC plus IL-2 and Interferon
Multiple Myeloma (Back to Top)
Protocol	Description
SWOG S0115	(Phase II) High Risk Multiple Myeloma/Amyloidosis: Modified High Dose Melphalan and Autologous Peripheral Blood Stem Cell Supported Transplant
SWOG S0204	(Phase II) Newly diagnosed Multiple Myeloma: Thalidomide/Dexamethasone induction followed by Tandem Melphalan Transplant & Prednisone/Thalidomide maintenance
Pancreatic Cancer (Back to Top)
Protocol	Description
SWOG 0205	(Phase III) Advanced Pancreatic Cancer: Gemcitabine plus C225 vs. Gemcitabine alone.
PDT (Back to Top)
Protocol	Description
PDT-BE-2002	Barrett's esophagus: Optimization of Photodynamic Therapy (Contact M. Panjehpour, PhD, 865-541-1628)
Prostate Cancer (Back to Top)
Protocol	Description
RTOG 0126	Phase III, High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in patients treated for localized Prostate Cancer.
Prostate Prevention (Back to Top)
Protocol	Description
	No Current Clinical Trials in this Area.
Sarcomas (Back to Top)
Protocol	Description
No Current Clinical Trials in this Area.
UNKNOWN PRIMARY (Back to Top)
Protocol	Description
SCCC UNKPRI 12	(Phase III) Randomized comparison of Gemcitabine/Irinotecan followed by IRESSA® in the first-line treatment of patients with carcinoma of unknown primary site
Other Studies (Back to Top)
Protocol	Description
IMPACT Study (Amgen)	Evaluate the Effect of an e/Tablet on Quality of Care as Measured by Symptom Severity Assessment of Cancer Patients Receiving Chemotherapy.

---